Biomedical Informatics

discovery and impact

Results from OHDSI and perspectives for international data sharing projects

George Hripcsak, MD, MS

Biomedical Informatics, Columbia University

Medical Informatics Services, NewYork-Presbyterian

Columbia University Medical Center

NewYork-Presbyterian

Observational Health Data Sciences and Informatics (OHDSI, as “Odyssey”)

Mission: To improve health by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care

A multi-stakeholder, interdisciplinary, international collaborative with a coordinating center at Columbia University

Aiming for 1,000,000,000 patient data network

http://ohdsi.org

OHDSI's global research community

- >200 collaborators from 25 different countries
- Experts in informatics, statistics, epidemiology, clinical sciences
- Active participation from academia, government, industry, providers
- Over a billion records on >400 million unique patients in 80 databases

http://ohdsi.org/who-we-are/collaborators/

OHDSI's approach to **open science**



- Open science is about sharing the journey to evidence generation
- Open-source software can be part of the journey, but it's not a final destination
- Open processes can enhance the journey through improved reproducibility of research and expanded adoption of scientific best practices

Evidence OHDSI seeks to generate from observational data

- **Clinical characterization = tallying**
  - Natural history: Who has diabetes, and who takes metformin?
  - Quality improvement: What proportion of patients with diabetes experience complications?
- **Population-level estimation = causality**
  - Safety surveillance: Does metformin cause lactic acidosis?
  - Comparative effectiveness: Does metformin cause lactic acidosis more than glyburide?
- **Patient-level prediction = prediction**
  - Precision medicine: Given everything you know about me, if I take metformin, what is the chance I will get lactic acidosis?
  - Disease interception: Given everything you know about me, what is the chance I will develop diabetes?

How OHDSI Works



Deep information model
OMOP CDM v5



Extensive vocabularies (80)

Breakdown of OHDSI concepts by domain, standard class, and vocabulary



Vocabulary

- SNOMED-CT
  - OHDSI's reference terminology for conditions (diagnoses) …
  - Mappings from ICD10, ICD10-CM, ICD9-CM, Read, MedDRA, …
    - Maintained by US Nat'l Library of Medicine and OHDSI
  - Retain the original term, but most research on the SNOMED term
  - Not need language-specific version
- Similar for RxNorm (drug), LOINC (lab), …

Tools to convert your data



OHDSI tools built to help

WhiteRabbit: profile your source data

RabbitInAHat: map your source structure to CDM tables and fields

ATHENA: standardized vocabularies for all CDM domains

Usagi: map your source codes to CDM vocabulary

CDM: DDL, index, constraints for Oracle, SQL Server, PostgresQL; Vocabulary tables with loading scripts

ACHILLES: profile your CDM data; review data quality assessment; explore population-level summaries

OHDSI Forums:
Public discussions for OMOP CDM Implementers/developers

http://github.com/OHDSI

Data Validation by ACHILLES Heel

Data Quality Messages

Search: Show / hide columns

Message Type	Message
ERROR	101-Number of persons by age, with age at first observation period; should not have age < 0, (n=848)
ERROR	103 - Distribution of age at first observation period (count = 1); min value should not be negative
ERROR	114-Number of persons with observation period before year-of-birth; count (n=851) should not be > 0
ERROR	206 - Distribution of age by visit_concept_id (count = 7); min value should not be negative
ERROR	301-Number of providers by specialty concept_id; 224 concepts in data are not in correct vocabulary (Specialty)
ERROR	400-Number of persons with at least one condition occurrence, by condition_concept_id; 115 concepts in data are not in correct vocabulary (SNOMED)
ERROR	406 - Distribution of age by condition_concept_id (count = 753); min value should not be negative

ATLAS to build, visualize, and analyze cohorts



Characterize the cohorts of interest

OHDSI Heracles

«Back
Refresh
Heracles Runner

Dashboard
Cohort Specific
Heracles Heel
Person
Observation Periods
Data Density
Condition
Condition Eras
Observations
Drug Eras
Drug Exposures
Procedures
Visits
Death

Alzheimers

Source: **INPC**

Number of Persons:
145,246

Year of Birth



Population by Gender



Population by Race



Population by Ethnicity



OHDSI in Action

Treatment Pathways



OHDSI in action: Chronic disease treatment pathways

- Conceived at AMIA 15Nov2014
- Protocol written, code written and tested at 2 sites 30Nov2014
- Analysis submitted to OHDSI network 2Dec2014
- Results submitted for 7 databases 5Dec2014

OHDSI partners for this query (250M)

Abbre-viation	Name	Description	Population, millions
AUSOM	Ajou University School of Medicine	South Korea; inpatient hospital EHR	2
CCAE	MarketScan Commercial Claims and Encounters	US private-payer claims	119
CPRD	UK Clinical Practice Research Datalink	UK; EHR from general practice	11
CUMC	Columbia University Medical Center	US; inpatient EHR	4
GE	GE Centricity	US; outpatient EHR	33
INPC	Regenstrief Institute, Indiana Network for Patient Care	US; integrated health exchange	15
JMDC	Japan Medical Data Center	Japan; private-payer claims	3
MDCD	MarketScan Medicaid Multi-State	US; public-payer claims	17
MDCR	MarketScan Medicare Supplemental and Coordination of Benefits	US; private and public-payer claims	9
OPTUM	Optum ClinFormatics	US; private-payer claims	40
STRIDE	Stanford Translational Research Integrated Database Environment	US; inpatient EHR	2
HKU	Hong Kong University	Hong Kong; EHR	1

Treatment pathway event flow



Proceedings of the National Academy of Sciences, 2016

PNAS

COLLOQUIUM PAPER

Characterizing treatment pathways at scale using the OHDSI network

George Hripcsak[a,b,c,1], Patrick B. Ryan[c,d], Jon D. Duke[c,e], Nigam H. Shah[c,f], Rae Woong Park[c,g], Vojtech Huser[c,h], Marc A. Suchard[c,i,j,k], Martijn J. Schuemie[c,d], Frank J. DeFalco[c,d], Adler Perotte[a,c], Juan M. Banda[c,f], Christian G. Reich[c,l], Lisa M. Schilling[c,m], Michael E. Matheny[c,n,o], Daniella Meeker[c,p,q], Nicole Pratt[c,r], and David Madigan[c,s]

[a]Department of Biomedical Informatics, Columbia University Medical Center, New York, NY 10032; [b]Medical Informatics Services, NewYork-Presbyterian Hospital, New York, NY 10032; [c]Observational Health Data Sciences and Informatics, New York, NY 10032; [d]Epidemiology Analytics, Janssen Research and Development, Titusville, NJ 08560; [e]Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN 46205; [f]Center for Biomedical Informatics Research, Stanford University, CA 94305; [g]Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea, 443-380; [h]Lister Hill National Center for Biomedical Communications (National Library of Medicine), National Institutes of Health, Bethesda, MD 20894; [i]Department of Biomathematics, University of California, Los Angeles, CA 90095; [j]Department of Biostatistics, University of California, Los Angeles, CA 90095; [k]Department of Human Genetics, University of California, Los Angeles, CA 90095; [l]Real World Evidence Solutions, IMS Health, Burlington, MA 01809; [m]Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045; [n]Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37212; [o]Geriatric Research, Education and Clinical Center, VA Tennessee Valley Healthcare System, Nashville, TN 37212; [p]Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90089; [q]Department of Pediatrics, University of Southern California, Los Angeles, CA 90089; [r]Division of Health Sciences, University of South Australia, Adelaide, SA, Australia 5001; and [s]Department of Statistics, Columbia University, New York, NY 10027

Edited by Richard M. Shiffrin, Indiana University, Bloomington, IN, and approved April 5, 2016 (received for review June 14, 2015)

Observational research promises to complement experimental research by providing large, diverse populations that would be infeasible for an experiment. Observational research can test its own clinical hypotheses, and observational studies also can contribute to the design of experiments and inform the generalizability of experimental research. Understanding the diversity of populations

Without sufficiently broad databases available in the first stage, randomized trials are designed without explicit knowledge of actual disease status and treatment practice. Literature reviews are restricted to the population choices of previous investigations, and pilot studies usually are limited in scope. By exploiting the ClinicalTrials.gov national trial registry (9) and electronic health

Treatment pathways for diabetes

T2DM : All databases



- Metformin
- pioglitazone
- sitagliptin
- Glipizide
- glimepiride
- Gliclazide
- Glyburide
- rosiglitazone
- Insulin, Glargine, Human
- exenatide
- Insulin, Aspart, Human
- liraglutide
- saxagliptin
- Insulin, Lispro, Human
- Glucose
- Insulin, Isophane, Human

Population-level heterogeneity across systems, and patient-level heterogeneity within systems



Patient-level heterogeneity

HTN: All databases



Lisinopril
Hydrochlorothiazide
Amlodipine
Metoprolol
Atenolol
Furosemide
Ramipril
Bendroflumethiazide
Losartan
valsartan
Triamterene
olmesartan
benazepril
Diltiazem
carvedilol
Bisoprolol
Doxazosin
Enalapril

25% of HTN patients (10% of others) have a unique path despite 250M pop

Monotherapy – diabetes

General upward trend in monotherapy



AUSOM (SKorea*) CCAE (US#) CPRD (UK*) CUMC (US*)
GE (US*) INPC (US*#) JMDC (Japan#) MDCD (US#)
MDCR (US#) OPTUM (US#) STRIDE (US*)

Monotherapy – HTN

Academic medical centers differ from general practices



AUSOM (SKorea*) CCAE (US#) CPRD (UK*) CUMC (US*)
GE (US*) INPC (US*#) JMDC (Japan#) MDCD (US#)
MDCR (US#) OPTUM (US#) STRIDE (US*)

Monotherapy – diabetes

General practices, whether EHR or claims, have similar profiles



AUSOM (SKorea*) CCAE (US#) CPRD (UK*) CUMC (US*)
GE (US*) INPC (US*#) JMDC (Japan#) MDCD (US#)
MDCR (US#) OPTUM (US#) STRIDE (US*)

Conclusions: Network research

- It is feasible to encode the world population in a single data model
  - Over 1,000,000,000 records by voluntary effort
- Generating evidence is feasible
- Stakeholders willing to share results
- Able to accommodate vast differences in privacy and research regulation

What is the quality of the current evidence from observational analyses?

ORIGINAL CONTRIBUTION

JAMA®

Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer

Chris R. Cardwell, PhD
Christian C. Abnet, PhD
Marie M. Cantwell, PhD
Liam J. Murray, MD

Context Use of oral bisphosphonates has increased dra
and elsewhere. Esophagitis is a known adverse effect of
cent reports suggest a link between bisphosphonate us
this has not been robustly investigated.

Objective To investigate the association between bis
ageal cancer.

Design, Setting, and Participants Data were ext

August2010: "Among patients in the UK General Practice Research Database, the use of oral bisphosphonates was not significantly associated with incident esophageal or gastric cancer"

sembles ground alendronate tablets has been found on biopsy in patients with bisphosphonate-related esophagitis, and follow-up endoscopies have shown that abnormalities remain after the esophagitis heals.[6] Reflux esophagitis is an established risk factor for esophageal cancer through the Barrett pathway.[7-9] It is not known whether bisphosphonate-related esophagitis can also increase esophageal cancer risk. However, the US Food and Drug Administration recently reported 23 cases of esophageal cancer (between 1995 and 2008) in patients using the bisphosphonate alendronate and a further 31 cases in pa-

cohort. The incidence of esophageal and gastric cancer
person-years of risk in both the bisphosphonate and c
of esophageal cancer alone in the bisphosphonate a
and 0.44 per 1000 person-years of risk, respectively. T
of esophageal and gastric cancer combined between
phonate use (adjusted hazard ratio, 0.96 [95% confid
risk of esophageal cancer only (adjusted hazard ratio,
val, 0.77-1.49]). There also was no difference in risk of
by duration of bisphosphonate intake.

Conclusion Among patients in the UK General Practic
of oral bisphosphonates was not significantly associate
gastric cancer.

JAMA. 2010;304(6):657-663

Large studies with appropriate comparison groups, adequate follow-up, robust characterization of bisphospho-

termine w
crease esop
dertook su

BMJ

RESEARCH

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

Jane Green, clinical epidemiologist,[1] Gabriela Czanner, statistician,[1] Gillian Reeves, statistical epidemiologist,[1] Joanna Watson, epidemiologist,[1] Lesley Wise, manager, Pharmacoepidemiology Research and Intelligence Unit,[2] Valerie Beral, professor of cancer epidemiology[1]

ABSTRACT

Objective To examine the hypothesis that risk of oesophageal, but not of gastric or colorectal, cancer is increased in users of oral bisphosphonates.

Design Nested case-control analysis within a primary care cohort of about 6 million people in the UK, with prospectively recorded information on prescribing of bisphosphonates.

Setting UK General Practice Research Database cohort.

Participants Men and women aged 40 years or over—2954 with oesophageal cancer, 2018 with gastric cancer, and 10 641 with colorectal cancer, diagnosed in 1995-2005; five controls per case matched for age, sex, general practice, and observation time.

Main outcome measures Relative risks for incident invasive cancers of the oesophagus, stomach, and colorectum, adjusted for smoking, alcohol, and body mass index.

Conclusions The risk of oesophageal cancer increased with 10 or more prescriptions for oral bisphosphonates and with prescriptions over about a five year period. In Europe and North America, the incidence of oesophageal cancer at age 60-79 is typically 1 per 1000 population over five years, and this is estimated to increase to about 2 per 1000 with five years' use of oral bisphosphonates.

INTRODUCTION

Adverse gastrointestinal effects are common among people who take oral bisphosphonates for the prevention and treatment of osteoporosis; they range from dyspepsia, nausea, and abdominal pain to erosive oesophagitis and oesophageal ulcers.[1] Recent case reports have suggested a possible increase in the risk of oesophageal cancer with use of such bisphosphonate preparations.[2] We report here on the relation between prospectively recorded prescribing information for

Sept2010: "In this large nested case-control study within a UK cohort [General Practice Research Database], we found a significantly increased risk of oesophageal cancer in people with previous prescriptions for oral bisphosphonates"

0.87 (0.64 to 1.19) and 0.87 (0.77 to 1.00). The specificity ... hospital records) are around 95% valid and

Open science

- Admit that there is a problem
- Study it scientifically
  - Define that surface and differentiate true variation from confounding …
- Total description of every study
- Research into new methods

Take a scientific approach to science

1. Database heterogeneity:
   Holding analysis constant, different data may yield different estimates

Madigan D, Ryan PB, Schuemie MJ et al, American Journal of Epidemiology, 2013
"Evaluating the Impact of Database Heterogeneity on Observational Study Results"

2. Parameter sensitivity:
   Holding data constant, different analytic design choices may yield different estimates

Madigan D, Ryan PB, Schuemie MJ, Therapeutic Advances in Drug Safety, 2013: "Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies"

3. Empirical performance:
   Most observational methods do not have nominal statistical operating characteristics

Ryan PB, Stang PE, Overhage JM et al, Drug Safety, 2013:
"A Comparison of the Empirical Performance of Methods for a Risk Identification System"

4. Empirical calibration can help restore interpretation of study findings

Schuemie MJ, Ryan PB, DuMouchel W, et al, Statistics in Medicine, 2013:
"Interpreting observational studies: why empirical calibration is needed to correct p-values"

Reproducible research

1. Address confounding that is measured

- **Propensity stratification**
- ***Systematic* (not manual) variable selection**
  - **Balance 58,285 variables ("Table 1")**





Reproducible research

2. Unmeasured (residual) **confounding**

- **Confidence interval calibration**
  - **Adjust for all uncertainty, not just sampling**
- **Many negative controls**
  - **Unique to OHDSI** (PNAS in press)



Reproducible research

3. Multiple databases, locations, practice types

- **Exploit international OHDSI network**



Reproducible research

4. Open: publish all

- **Hypotheses**
- **Code**
- **Parameters**
- **Runs**



Generating evidence for US FDA

Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) between October - December 2015

Keppra (levetiracetam) tablet, oral solution, injection	Angioedema	FDA is evaluating the need for regulatory action.

- Protocol completed, code tested, study announced



OHDSI Study: Levetiracetam and Risk of Angioedema in patients with Seizure Disorder

Researchers

jon_duke — May '16

Good afternoon OHDSI researchers!

We are pleased to announce the official start of the Keppra and Angioedema study! See full details on the wiki including study rationale, protocol, and code.

So far we have participation from UCLA, Columbia University, Regenstrief, and Janssen. We would be delighted for you to join!

If you have any questions, please respond via this thread.

Thanks,

Jon, Martijn, Marc, Patrick, George

- 50 viewed protocol, 25 viewed the code, and 7 sites ran the code on 10 databases (5 claims / 5 EHR), 59,367 levetiracetam patients matched with 74,550 phenytoin patients

Generating evidence for US FDA

No evidence of increased angioedema risk with levetiracetam use compared with phenytoin use

"The study is focused, appears well designed, and provides new insight that should be of interest to clinicians and regulators... This is an important contribution to improved pharmacovigilance."

Add word to title, move diagram from supplement to body

How can we improve the literature

Literature


Standard error
1.5
1.0
0.5
0.0
0.25
0.5
1
2
4
6
8
10
Effect size (1 = no effect)
P = 0.05

Literature


Standard error
1.5
1.0
0.5
0.0
Not significant
P = 0.05
Protect
Harm
0.25
0.5
1
2
4
6
8
10
Effect size

Observational research results in literature



29,982 estimates
11,758 papers

Observational research results in literature



Publication bias

- Don't know the denominator of negative studies.

29,982 estimates
11,758 papers

Observational research results in literature



P-value hacking

29,982 estimates
11,758 papers

Observational research results in literature

- Individuals may produce good research studies
- In aggregate, the medical research system is a data dredging machine

Look at many outcomes at once

Duloxetine vs. Sertraline for these 22 outcomes:

Acute liver injury	Hypotension
Acute myocardial infarction	Hypothyroidism
Alopecia	Insomnia
Constipation	Nausea
Decreased libido	Open-angle glaucoma
Delirium	Seizure
Diarrhea	Stroke
Fracture	Suicide and suicidal ideation
Gastrointestinal hemorrhage	Tinnitus
Hyperprolactinemia	Ventricular arrhythmia and sudden cardiac death
Hyponatremia	Vertigo

Many treatments at once

Type	Class	Treatment
Drug	Atypical	Bupropion
Drug	Atypical	Mirtazapine
Procedure	ECT	Electroconvulsive therapy
Procedure	Psychotherapy	Psychotherapy
Drug	SARI	Trazodone
Drug	SNRI	Desvenlafaxine
Drug	SNRI	duloxetine
Drug	SNRI	venlafaxine
Drug	SSRI	Citalopram
Drug	SSRI	Escitalopram
Drug	SSRI	Fluoxetine
Drug	SSRI	Paroxetine
Drug	SSRI	Sertraline
Drug	SSRI	vilazodone
Drug	TCA	Amitriptyline
Drug	TCA	Doxepin
Drug	TCA	Nortriptyline

Large-scale estimation for depression

- 17 **treatments**
- 17 * 16 = 272 comparisons
- 22 **outcomes**
- 272 * 22 = 5,984 effect size estimates
- 4 **databases** (Truven CCAE, Truven MDCD, Truven MDCR, Optum)
- 4 * 5,984 = **23,936 estimates**

Estimates are in line with expectations

11% of exposure-outcome pairs have calibrated p < 0.05





Example



Mirtazapine vs. Citalopram
Constipation

Database: Truven MDCD

Calibrated HR = 0.90 (0.70 – 1.12)









Propensity models for all comparisons (Truven CCAE, one outcome)



Large-scale estimation for depression

- How do we use it? Troll for effects?
- Professor what should I study this year?
  - Simple, go to Pubmed and find the smallest p-values in the literature; surely those must be the most significant things to study
- Which is safer?
  - Seizure in 0.0000000001 to 0.0000000002 (p=0.00001)
  - Seizure in 0 to 0.2 (p=.45)
- Large-scale studies become the literature
  - Come with hypothesis and ask a question

Large-scale estimation for depression

- Not “data-dredging”!
  - Data-dredging is not about what you do but about what you *throw out*
    - This can’t be done for literature
- One-off studies
  - Wouldn’t it be best to optimize each study?
    - Never get 10 or 100 parameters right
  - Still good to see the distribution
- At the very least, publish every last parameter so it can be reproduced

How often

How often do side effects occur?

- New incidence of any condition for any drug on the world market
  - Show range of answers for disparate databases
- Absolute risk (vs. attributable risk)
  - Not know if it is causal or not: MI with statin
- More complicated than it looks
  - Standard framework for reporting incidence



howoften.org

OHDSI



International data sharing

International data sharing

- Research benefits from diversity
  - Climate and other environment
  - Culture
  - Genetics
  - Health care policy
  - Socioeconomic disparities
  - Care setting
  - Data capture process

International data sharing

- Language
  - Collected and developed mappings from 80 vocabularies to small number of standards
  - >$250K/year + volunteer work
  - Free on Athena on OHDSI.org

International data sharing

- Common data model
  - International community to assist in ETL



International data sharing

- Privacy
  - Keep data local
  - Distribute queries

International data sharing

- Governance
  - Workgroups and forums
    - Many require two per period to cover time zones
  - Coordinating center to pay the bills

Tradeoff on data standardization

- More constrained common data model
- Deep information model
  - Schema, vocabularies, conventions
- More time to convert and verify data
- Greatly aids research
- For worldwide research, need agreement

Opportunities for standardization

- **Data structure**: tables, fields, data types
- **Data conventions**: set of rules that govern how data are represented
- **Data vocabularies**: terminologies to codify clinical domains
- **Cohort definition**: algorithms for identifying the set of patients who meet a collection of criteria for a given interval of time
- **Covariate construction**: logic to define variables available for use in statistical analysis
- **Analysis**: collection of decisions and procedures required to produce aggregate summary statistics from patient-level data
- **Results reporting**: series of aggregate summary statistics presented in tabular and graphical form

OHDSI Uptake

- Good uptake in the US
  - OHDSI network sites
  - All of Us Research Program
  - eMERGE Consortium
  - FDA Sentinel BEST contract
  - PCORnet sources
- Good uptake in Asia
  - South Korea
  - Taiwan
  - Hong Kong
  - Japan database
  - China
  - Australia
- Europe
  - Netherlands
  - Sweden
  - Italy
  - UK database
  - EMA investigation
  - IMI
  - Germany …

Summary on OHDSI

- Successful international clinical data collaboration
- Open source tools including mappings (free)
- Producing evidence today
- Can influence the future of OHDSI

OHDSI.org